Changes in Renal Perfusion During Hemodialysis in Patients with End-stage Renal Disease

Not yet recruiting

• Conditions: End-stage Renal Disease

• Registration Number: NCT06587997
• Lead Sponsor: Yuanjun Yang

Brief Summary

Residual renal function (RRF) characteristically declines after patients with end-stage renal disease (ESRD) initiate dialysis. Although RRF preservation correlates with improved patient\'s quality of life and survival prospects, poor understanding of the pathophysiology underlying RRF decline limits protection strategies.

Detailed Description

Hemodialysis (HD) is the primary renal replacement therapy for patients with end-stage renal disease. However, residual renal function (RRF) characteristically declines after these individuals start dialysis. This loss of RRF not only impacts the adequacy of dialysis and control of complications but also affects the patient\'s quality of life and survival prospects. Due to a lack of clear understanding regarding the pathophysiology underlying this decline in RRF, no effective strategies exist for its preservation at present. The objective of this study is to explore the changes in renal perfusion during hemodialysis in patients with end-stage renal disease, and provide a new idea for protection of RRF. This study was an observational study, and no interventions were performed.

Study Timeline

• Status Verified: 2024-09
• Study Start: 2024-09-05
• Study First Submitted: 2024-09-05
• Study First Submitted QC: 2024-09-05
• Last Update Submitted: 2024-09-05
• Study First Posted: 2024-09-09
• Last Update Posted: 2024-09-09
• Primary Completion: 2026-09-03
• Study Completion: 2026-09-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Age ≥ 18 years;
• Clinical diagnosis of end-stage renal disease requiring long-term hemodialysis treatment, with dialysis duration ≤ 3 months;
• Urine output > 500ml/day or GFR > 3ml/min/1.72m2;
• Signed and dated informed consented is obtained.

Exclusion Criteria

• Presence of vascular access dysfunction (blood flow rate < 180ml/min);
• Severe heart failure;
• Active infection;
• Infectious disease;
• Patients with severe anemia;
• Patients with polycystic kidney disease;
• Expected dialysis duration < 6 months;
• Pregnancy or lactation women;
• Patients who are participating in other clinical studies, or who have participated in other clinical studies within 3 months prior to enrollment;
• Unwillingness to be followed up or poor adherence to treatment;
• Other circumstances that the investigator considers unsuitable for enrolment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
renal perfusion	one day	Changes in renal perfusion during hemodialysis in patients with end-stage renal disease

Secondary Outcome Measures

Name	Time	Method
diastolic blood pressure	one day	diastolic blood pressure during hemodialysis in patients with end-stage renal disease
systolic blood pressure	one day	systolic blood pressure during hemodialysis in patients with end-stage renal disease
urine volume	10 months	Urine volume within 10 months of starting dialysis